These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12601441)

  • 1. Cost effectiveness in Canada of eptifibatide treatment for acute coronary syndrome patients using PURSUIT subgroup analysis.
    Brown R; Armstrong P;
    Can J Cardiol; 2003 Feb; 19(2):161-6. PubMed ID: 12601441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes.
    Plosker GL; Ibbotson T
    Pharmacoeconomics; 2003; 21(12):885-912. PubMed ID: 12908844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy.
    Brown RE; Henderson RA; Koster D; Hutton J; Simoons ML
    Eur Heart J; 2002 Jan; 23(1):50-8. PubMed ID: 11741362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes.
    Mark DB; Harrington RA; Lincoff AM; Califf RM; Nelson CL; Tsiatis AA; Buell H; Mahaffey KW; Davidson-Ray L; Topol EJ
    Circulation; 2000 Feb; 101(4):366-71. PubMed ID: 10653826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Costs and cost-effectiveness of Eptifibatide in the treatment of coronary ischemic syndromes. An analysis based on the PURSUIT study].
    Szucs TD; Schwenkglenks M; Berger K; Karsch K
    Z Kardiol; 2003 Mar; 92(3):236-44. PubMed ID: 12658471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of patients with non-ST-segment elevation acute coronary syndromes: insights from the PURSUIT trial.
    Fintel DJ; Ledley GS
    Clin Cardiol; 2000 Sep; 23 Suppl 5(Suppl 5):V1-12. PubMed ID: 11019716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
    Lauer MA; Houghtaling PL; Peterson JG; Granger CB; Bhatt DL; Sapp SK; Simoons ML; Harrington RA; Topol EJ; Lincoff AM;
    Circulation; 2001 Dec; 104(23):2772-7. PubMed ID: 11733393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
    Harrington RA
    Am J Cardiol; 1997 Aug; 80(4A):34B-38B. PubMed ID: 9291244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.
    Giugliano RP; Newby LK; Harrington RA; Gibson CM; Van de Werf F; Armstrong P; Montalescot G; Gilbert J; Strony JT; Califf RM; Braunwald E;
    Am Heart J; 2005 Jun; 149(6):994-1002. PubMed ID: 15976780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes. Estimating the economic implications.
    Hillegass WB; Newman AR; Raco DL
    Pharmacoeconomics; 2001 Jan; 19(1):41-55. PubMed ID: 11252545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial.
    Fitchett DH; Langer A; Armstrong PW; Tan M; Mendelsohn A; Goodman SG;
    Am Heart J; 2006 Feb; 151(2):373-9. PubMed ID: 16442903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
    Labinaz M; Kilaru R; Pieper K; Marso SP; Kitt MM; Simoons ML; Califf RM; Topol EJ; Armstrong PW; Harrington RA
    Circulation; 2002 Jan; 105(3):322-7. PubMed ID: 11804987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators.
    Hasdai D; Holmes DR; Criger DA; Topol EJ; Califf RM; Wilcox RG; Paolasso E; Simoons M; Deckers J; Harrington RA
    Am Heart J; 2000 Mar; 139(3):454-60. PubMed ID: 10689260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Present and evolving role of eptifibatide in the treatment of acute coronary syndromes.
    Tricoci P; Newby LK; Kandzari DE; Harrington RA
    Expert Rev Cardiovasc Ther; 2007 May; 5(3):401-12. PubMed ID: 17489665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
    Curran MP; Keating GM
    Drugs; 2005; 65(14):2009-35. PubMed ID: 16162023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
    Mahaffey KW; Harrington RA; Simoons ML; Granger CB; Graffagnino C; Alberts MJ; Laskowitz DT; Miller JM; Sloan MA; Berdan LG; MacAulay CM; Lincoff AM; Deckers J; Topol EJ; Califf RM
    Circulation; 1999 May; 99(18):2371-7. PubMed ID: 10318656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.
    Glaser R; Glick HA; Herrmann HC; Kimmel SE
    J Am Coll Cardiol; 2006 Feb; 47(3):529-37. PubMed ID: 16458131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on eptifibatide in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
    Curran MP; Keating GM
    BioDrugs; 2006; 20(1):63-5. PubMed ID: 16573353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Economic evaluation of eptifibatide].
    Villar FA; Botella FA
    Rev Esp Cardiol; 2001 Feb; 54(2):169-74. PubMed ID: 11181305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial.
    Labinaz M; Kaul P; Harrington RA; Chang WC; Kleiman NS; Simoons ML; Boersma E; Akkerhuis KM; Califf RM; Armstrong PW;
    Can J Cardiol; 2004 Jun; 20(8):773-8. PubMed ID: 15229770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.